Ulcerative colitis Ulcerative colitis
Conditions
Interventions
arm A :stop oral administration of indigo naturalis
arm B :continue oral administration of indigo naturalis
Controlled clinical trial
Sponsors
Kitazono Takanari
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who undergo the treatment of Qing-Dai over a year 2) Patients whose disease activity is 1 or 0 by Mayo endoscopic score 3) Patients who received full-explanation and completely understood the study. 4) Patients with no change in treatment within the past 2 weeks before the commencement of the study 5) Patients with no change in treatment of ulcerative colitis during their oral administration of Qing-Dai 6) Patients who have voluntarily submitted written consent forms upon participation in this study
Exclusion criteria
Exclusion criteria: 1)Pregnant or breastfeeding women 2)Patients who have a history of psychosomatic disorders 3)Patients who have a history of liver or renal diseases 4)Patients who have a history of antithrombotic therapy or thrombocytopenia 5)Patients who have a history of hepatitis B 6)Patients whom investigators and subinvestigators considered inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| remission rate after week 52 after initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| remission rate at week 152 after initiation, remission rate at week 4 after re-induction therapy | — |
Contacts
Public ContactYuichi Matsuno
Graduate School of Medical Sciences,Kyushu University
Outcome results
None listed